Acute Myocarditis Following the Administration of the Second BNT162b2 COVID-19 Vaccine Dose

Cureus. 2021 Oct 18;13(10):e18880. doi: 10.7759/cureus.18880. eCollection 2021 Oct.


COVID-19 disease has infected millions of people worldwide during the pandemic; hence, the need for an effective and safe vaccine was urgently required. A two-dose of the BNT162b2 mRNA COVID-19 vaccine was reported to have 95% efficacy in preventing COVID-19. The short-term safety profile recorded mild to moderate pain at the injection site, fatigue, and headache. The critical adverse effects were low and similar in the placebo group. However, we report the case of an 18-year-old male who developed acute central crushing chest pain four days following administration of the second dose of the BNT162b2 COVID-19 vaccine. After extensive cardiac workup, including coronary arteries diagnostic angiography, myocarditis was suspected and confirmed by a cardiac MRI. Fortunately, the patient's clinical condition gradually improved in the form of clinical symptoms and laboratory findings. He was discharged after one week of stay in hospital with regular follow-up in the cardiac clinic.

Keywords: bnt162b2; covid-19 vaccine; mrna vaccine; myocarditis; myopericarditis; sars-cov-2.

Publication types

  • Case Reports